Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response

Thumbnail
Date
2007-08-30
ICR Author
Crook, Timothy
Syed, Nelofer
Author
Gorrini, C
Squatrito, M
Luise, C
Syed, N
Perna, D
Wark, L
Martinato, F
Sardella, D
Verrecchia, A
Bennett, S
Confalonieri, S
Cesaroni, M
Marchesi, F
Gasco, M
Scanziani, E
Capra, M
Mai, S
Nuciforo, P
Crook, T
Lough, J
Amati, B
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
The acetyl-transferase Tip60 might influence tumorigenesis in multiple ways(1). First, Tip60 is a co-regulator of transcription factors that either promote or suppress tumorigenesis, such as Myc and p53(2-4). Second, Tip60 modulates DNA-damage response (DDR) signalling(1), and a DDR triggered by oncogenes can counteract tumour progression(5,6). Using E-mu-myc transgenic mice that are heterozygous for a Tip60 gene (Htatip) knockout allele (hereafter denoted as Tip60(+/-) mice), we show that Tip60 counteracts Myc-induced lymphomagenesis in a haplo-insufficient manner and in a time window that is restricted to a pre- or early-tumoral stage. Tip60 heterozygosity severely impaired the Myc-induced DDR7-9 but caused no general DDR defect in B cells. Myc- and p53-dependent transcription were not affected, and neither were Myc- induced proliferation, activation of the ARF-p53 tumour suppressor pathway or the resulting apoptotic response(10-13). We found that the human TIP60 gene (HTATIP) is a frequent target for mono-allelic loss in human lymphomas and head-and-neck and mammary carcinomas, with concomitant reduction in mRNA levels. Immunohistochemical analysis also demonstrated loss of nuclear TIP60 staining in mammary carcinomas. These events correlated with disease grade and frequently concurred with mutation of p53. Thus, in both mouse and human, Tip60 has a haplo-insufficient tumour suppressor activity that is independent from-but not contradictory with-its role within the ARF-p53 pathway(1-3,14-16). We suggest that this is because critical levels of Tip60 are required for mounting an oncogene-induced DDR in incipient tumour cells(5,6), the failure of which might synergize with p53 mutation towards tumour progression(17-20).
URI
https://repository.icr.ac.uk/handle/internal/2469
DOI
https://doi.org/10.1038/nature06055
Collections
  • Other ICR Research
Language
eng
License start date
2007-08-30
Citation
NATURE, 2007, 448 pp. 1063 - U12
Publisher
NATURE PUBLISHING GROUP

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.